Aptevo Therapeutics (NASDAQ:APVO) Vs. PRTK, TNXP, ATNF, ATNX, MLND, INZY, ANVS, INFI, MBIO, and ALZN
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Paratek Pharmaceuticals (PRTK), Tonix Pharmaceuticals (TNXP), 180 Life Sciences (ATNF), Athenex (ATNX), Millendo Therapeutics (MLND), Inozyme Pharma (INZY), Annovis Bio (ANVS), Infinity Pharmaceuticals (INFI), Mustang Bio (MBIO), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics vs.
Tonix Pharmaceuticals (NASDAQ:TNXP) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
Tonix Pharmaceuticals has a net margin of 0.00% compared to Aptevo Therapeutics' net margin of -265.80%. Tonix Pharmaceuticals' return on equity of -49.29% beat Aptevo Therapeutics' return on equity.
In the previous week, Aptevo Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 4 mentions for Aptevo Therapeutics and 3 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.00 beat Aptevo Therapeutics' score of -0.09 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.
Tonix Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 6.74, suggesting that its share price is 574% more volatile than the S&P 500.
Tonix Pharmaceuticals received 140 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 72.35% of users gave Tonix Pharmaceuticals an outperform vote while only 65.00% of users gave Aptevo Therapeutics an outperform vote.
Tonix Pharmaceuticals currently has a consensus target price of $2.00, suggesting a potential upside of 337.45%. Aptevo Therapeutics has a consensus target price of $36.00, suggesting a potential upside of 266.97%. Given Tonix Pharmaceuticals' higher probable upside, research analysts clearly believe Tonix Pharmaceuticals is more favorable than Aptevo Therapeutics.
20.8% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Aptevo Therapeutics shares are owned by institutional investors. 1.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aptevo Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals.
Summary
Aptevo Therapeutics beats Tonix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics (NASDAQ:APVO) vs. Its Competitors
Aptevo Therapeutics Competitors List
